Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Australia reaffirms its commitment to building resilient critical mineral supply chains and a strategic reserve, undeterred by the U.S. stepping back from plans to guarantee minimum prices for such projects.
As the European Central Bank prepares for its February meeting, policymakers are navigating a stronger euro driven by a weakening dollar and geopolitical uncertainty, while assessing the resilience of the eurozone economy.
First Internet Bancorp (INBK) reported a robust 21% surge in quarterly revenue, successfully managing an uptick in criticized loans while laying the groundwork for growth in its fintech and SBA lending segments for the coming year.
Panama's Supreme Court has nullified long-held port contracts operated by a CK Hutchison subsidiary, declaring them unconstitutional. The landmark ruling throws the future of key container terminals at both ends of the Panama Canal into doubt and reverberates amid broader geopolitical tensions over global trade chokepoints.
President Trump is preparing to nominate former Fed Governor Kevin Warsh to lead the central bank, according to people familiar with the discussions, a move that triggered immediate market reactions as investors assessed the potential policy shift.
The US dollar hits a multi-year low against the euro following President Trump's endorsement of a weaker currency, sparking debate over its impact on trade, inflation, and America's financial standing.
Amid renewed threats of steep US tariffs, South Korean officials are scrambling to salvage a key trade deal, with high-level talks in Washington failing to yield an immediate breakthrough.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
With his term winding down, Federal Reserve Chair Jerome Powell offered rare, pointed advice to his eventual successor during a recent press conference, emphasizing the imperative of maintaining the central bank's independence from political influence.
Gold prices have shattered records, breaching $5,000 per ounce as geopolitical tensions and shifting monetary policies drive a historic rally. Analysts debate whether this is a peak or a new foundation for the safe-haven asset.
The U.S. dollar extended its weekly decline as fresh geopolitical risks, including new tariff threats over Cuba and potential military action against Iran, dampened appetite for American assets, despite domestic political relief.
Once the engine of Venezuela's wealth, the communities around Lake Maracaibo now stand as decaying monuments to the nation's oil collapse. As a controversial U.S. plan promises a $100 billion investment, residents of the ghostly 'oil camps' are caught between desperate hope and deep-seated skepticism.
Brent crude surged above $70 a barrel for the first time since mid-2025, driven by escalating Middle East tensions and shifting supply dynamics, as analysts signal a fading bearish outlook for the oil market.
